APALUTAMIDE

Brand name:

• Erlyand®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Prostate cancer

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

Change to recommended PBS listing (Standard re-entry)

Comment:

--

Submission sponsor:

Janssen-Cilag Pty Ltd

Other PBAC consideration:

• APALUTAMIDE

Submission received for:

July 2022 PBAC meeting

Opportunity for consumer comment:

Open 30/03/2022 and close 25/05/2022 (see PBS Website)

PBAC meeting:

Held on 06/07/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

28/09/2022

Lodgement of required documentation:

18/10/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 27/10/2022

Status:

Finalised

Government processes:

Commenced on 27/02/2023

Medicine listed on the PBS:

01/06/2023 (see PBS schedule)

---